Scilex (SCLX) Competitors

C4 Therapeutics (NASDAQ:CCCC) and Scilex (NASDAQ:SCLX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, community ranking, media sentiment, earnings, dividends and profitability.

Does the media refer more to CCCC or SCLX?

In the previous week, C4 Therapeutics had 1 more articles in the media than Scilex. MarketBeat recorded 2 mentions for C4 Therapeutics and 1 mentions for Scilex. C4 Therapeutics' average media sentiment score of 0.59 beat Scilex's score of 0.00 indicating that C4 Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
C4 Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scilex	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Does the MarketBeat Community favor CCCC or SCLX?

C4 Therapeutics received 14 more outperform votes than Scilex when rated by MarketBeat users. However, 86.67% of users gave Scilex an outperform vote while only 38.57% of users gave C4 Therapeutics an outperform vote.

Company	Underperform	Outperform
C4 Therapeutics	Outperform Votes 27 38.57%	Underperform Votes 43 61.43%
Scilex	Outperform Votes 13 86.67%	Underperform Votes 2 13.33%

Which has higher valuation and earnings, CCCC or SCLX?

Scilex has higher revenue and earnings than C4 Therapeutics. C4 Therapeutics is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
C4 Therapeutics	$39.78M	2.64	-$132.49M	-$1.47	-1.01
Scilex	$50.71M	0.69	-$114.33M	-$29.02	-0.17

Which has more volatility & risk, CCCC or SCLX?

C4 Therapeutics has a beta of 3.1, meaning that its stock price is 210% more volatile than the S&P 500. Comparatively, Scilex has a beta of 1.1, meaning that its stock price is 10% more volatile than the S&P 500.

Do insiders and institutionals hold more shares of CCCC or SCLX?

78.8% of C4 Therapeutics shares are owned by institutional investors. Comparatively, 69.7% of Scilex shares are owned by institutional investors. 8.7% of C4 Therapeutics shares are owned by company insiders. Comparatively, 7.7% of Scilex shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Is CCCC or SCLX more profitable?

Scilex has a net margin of -159.10% compared to C4 Therapeutics' net margin of -313.35%. Scilex's return on equity of 0.00% beat C4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
C4 Therapeutics	-313.35%	-42.45%	-27.55%
Scilex	-159.10%	N/A	-93.65%

Do analysts rate CCCC or SCLX?

C4 Therapeutics presently has a consensus target price of $12.00, suggesting a potential upside of 710.81%. Scilex has a consensus target price of $455.00, suggesting a potential upside of 9,000.00%. Given Scilex's stronger consensus rating and higher possible upside, analysts clearly believe Scilex is more favorable than C4 Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
C4 Therapeutics	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
Scilex	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

C4 Therapeutics beats Scilex on 10 of the 18 factors compared between the two stocks.